Roehling, S.; Gahlert, M.; Bacevic, M.; Woelfler, H; Laleman, I.

Clinical and radiographic outcomes of zirconia dental implant : A systematic review and meta-analysis

Date of secondary publication: 18.04.2024
Version of Record (Published Version), Article
Persistent identifier: urn:nbn:de:bvb:473-irb-947836

Primary publication

Legal Notice
This work is protected by copyright and/or the indication of a licence. You are free to use this work in any way permitted by the copyright and/or the licence that applies to your usage. For other uses, you must obtain permission from the rights-holders.

This document is made available under a Creative Commons license.

The license information is available online: https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode
Clinical and radiographic outcomes of zirconia dental implants—A systematic review and meta-analysis

S. Roehling1,2,3 | M. Gahlert1,3,4 | M. Bacevic5,6,7 | H. Woelfler8 | I. Laleman5,9

1Clinic for Oral and Cranio-Maxillofacial Surgery, Hightech Research Center, University Hospital Basel, University of Basel, Basel, Switzerland
2Clinic for Oral and Cranio-Maxillofacial Surgery, Kantonsspital Aarau, Aarau, Switzerland
3Private Dental Clinic PD Dr. Gahlert & PD Dr. Roehling, Munich, Germany
4Sigmund Freud Private University, Vienna, Austria
5Department of Periodontology and Oral Surgery, Faculty of Medicine, University of Liège, Liège, Belgium
6Centre for Oral Clinical Research, Institute of Dentistry, London, UK
7Barts and The London School of Medicine and Dentistry, Queen Mary University of London (QMUL), London, UK
8University of Bamberg, Bamberg, Germany
9Dental Biomaterials Research Unit (d-BRU), Faculty of Medicine, University of Liège, Liège, Belgium

Correspondence
S. Roehling, Clinic for Oral and Cranio-Maxillofacial Surgery, Hightech Research Center, University Hospital Basel, University of Basel, Spitalstr. 21, Basel 4031, Switzerland.
Email: sr@oralchirurgie-t1.de

Abstract
Objectives: For the present review, the following focused question was addressed: In patients with root-analog dental implants, what is the effect of implants made of other materials than titanium (alloy) on implant survival, marginal bone loss (MBL), and technical and biological complications after at least 5 years.

Materials and Methods: An electronic (Medline, Embase, Web of Science) search was performed to identify observational clinical studies published from January 2000 investigating a minimum of 20 commercially available zirconia implants with a mean follow-up of at least 60 months. Primary outcome was implant survival, secondary outcomes included peri-implant MBL, probing depths (PDs), and technical and biological complications. Meta-analyses were performed to evaluate implant survival, MBL, and PD.

Results: From 5129 titles, 580 abstracts were selected, and 111 full-text articles were screened. Finally, 4 prospective and 2 retrospective observational clinical cohort studies were included for data extraction. Meta-analyses estimated after 5 years of loading mean values of 97.2% (95% CI 94.7–99.1) for survival (277 implants, 221 patients), 1.1 mm (95% CI: 0.9–1.3) for MBL (229 implants, 173 patients), and 3.0 mm (95% CI 2.5–3.4) for PDs (231 implants, 175 patients).

Conclusions: After 5 years, commercially available zirconia implants showed reliable clinical performance based on survival rates, MBL, and PD values. However, more well-designed prospective clinical studies and randomized clinical trials investigating titanium and zirconia implants are needed to confirm the presently evaluated promising outcomes.

Keywords: biological complications, dental implants, implant survival, marginal bone loss, meta-analysis, probing depths, technical complications, yttria stabilized tetragonal zirconia, zirconium oxide

1 | INTRODUCTION

For many decades, titanium has been used for the fabrication of dental implants and abutments. In recent years, esthetic outcomes — especially in the anterior region — have become very important. The dark grayish color of titanium implants and abutments can be a major drawback regarding white and pink esthetics (Glauser et al., 2004; Jung et al. 2008). However, not only the focus on...
esthetics but also the biological awareness of clinicians and patients has changed. Metals like commercially pure titanium or specific titanium-zirconium alloy show very good soft and hard tissue integration capacities and excellent clinical performance (Roehling et al., 2015). However, concerns have been raised regarding the potential of titanium to induce hypersensitivity or inflammatory reactions in the host tissues which could lead to various biological complications. In addition, an association between plaque, biocorrosion, presence of titanium particles, and biological implant complications has been reported (Mombelli et al., 2018).

In clinical studies, alumina and zirconia have been investigated as implant materials other than titanium or titanium-zirconium. Alumina implants were established on the market at the end of the 1960s and were clinically used until the beginning of the 1990s (De Wijs et al., 1994). At the beginning of 2004, zirconia was established on the market as an implant material and is currently the only material that is used for the fabrication of ceramic dental implants with 1- and 2-piece designs. Based on superior biomechanical properties, zirconia implants can withstand oral occlusal forces (Kohal et al., 2015). So far, systematic investigations concerning the clinical performance of zirconia implants estimated mean survival rates between 95% and 97.2% only for follow-up periods of 1 and 2 years (Pieralli et al., 2017; Roehling et al., 2018). However, even though meta-analyses are limited to 1 and 2 years of follow-up, clinical studies investigating zirconia implants after functional loading periods of 5 years and more have most recently been published (Brunello et al., 2022; Gahlert et al., 2022). So far, no systematic reviews and meta-analyses evaluating the clinical and radiographic performance of zirconia implants after follow-up periods of more than 2 years are available.

The intended focused question for this invited review (2023 ITI consensus conference) was: “In clinical studies, what other materials compared to commercially pure titanium, or a specific titanium alloy allow peri-implant soft and hard tissue integration?” However, due to the large heterogeneity of the available abutment and implant studies (several randomized controlled clinical trials available investigating abutments, while this is not the case for the commercially available implant materials), it was not possible to combine both topics. Consequently, the focused question was answered in two separate systematic reviews. The present manuscript reports data on implant materials, while information regarding abutment materials will be the subject of another systematic review (Laleman et al.).

For the present systematic review, the focused question to be addressed was as follows:

In patients with root-analog dental implants, what is the effect of implants made of other materials than titanium or a specific titanium alloy on implant survival, marginal bone loss (MBL), and technical and biological complications after at least 5 years?

### 2 | MATERIALS AND METHODS

This systematic review was conducted according to the Preferred Reporting Items for Systematic review and Meta-Analysis Protocols (PRISMA-P (Page et al., 2021) statement using the Population, Intervention, Comparison and Outcome (PICO) method (Schardt et al., 2007). The protocol for this systematic review was registered on PROSPERO (CRD42022376487).

#### 2.1 | Search strategy

An electronic, systematic search of Medline via Pubmed, Embase via Elsevier and Web of Science via Clarivate databases was performed in July 2022. The specific search terms are found in Appendix S1.

Additional hand searches were performed and included the following: bibliographies of previous reviews on the subject and bibliographies of all included full-text articles. Moreover, a manual search of the reference lists of relevant articles published in Clinical Oral Implants Research, International Journal of Oral & Maxillofacial Implants, Clinical Implant Dentistry and Related Research, Journal of Periodontology, and Journal of Clinical Periodontology was performed.

#### 2.2 | Eligibility criteria

##### 2.2.1 | Implant studies

For the part of the systematic review focusing on the implants, the following inclusion criteria were defined:

- Human, observational trials (prospective and retrospective) investigating implants made of materials other than commercially pure grade 4 titanium or specific titanium alloys published from January 2000.
- Implant types and surface topographies investigated in the included studies have not been removed from the market, respectively, replaced on the market by a further developed, next generation of the same type of implant.
- At least 20 implants were evaluated at follow-up.
- Follow-up for at least 60 months after implant placement.
- Reported details regarding implant survival.
- Reported details regarding peri-implant marginal bone loss.
- Language: English.

Studies not meeting the inclusion criteria were excluded from the review. Moreover, clinical studies investigating individually designed zirconia implants or multiple publications on the same patient population, as well as investigations based on charts, questionnaires, or interviews as well as case reports were excluded. Due to time limitations and invited systematic review, only articles published in the English language could be included in the present manuscript.

##### 2.2.2 | Selection of studies

After the elimination of duplicates, the reviewers (SR, IL) independently screened titles, abstracts, and full texts meeting the selection criteria. For the screening of titles and abstracts, the free web and mobile
Implant failures were classified as follows:

- Type 1: Immediate implant placement following tooth extraction.
- Type 2: Early implant placement after complete soft tissue healing (4–8 weeks).
- Type 3: Early implant placement after partial bone healing (12–16 weeks).
- Type 4: Late implant placement after complete bone healing (more than 16 weeks).

Implant loading protocols were classified as follows by (Weber et al., 2009):

- Immediate loading: Functional loading of implants earlier than 1 week subsequent to implant placement.
- Early loading: Functional loading of implants between 1 week and 2 months subsequent to implant placement.
- Conventional loading: Functional loading after more than 2 months subsequent to implant placement.

Implant failures were classified as follows:

- Early implant failures: Implant loss before prosthetic loading (Broggini et al., 2007).
- Late implant failures: Implant loss after prosthetic loading (Broggini et al., 2007).
- Implant fractures.

Data extraction by the reviewers was independently performed for all included studies (SR, IL) using data extraction tables. Disagreement regarding data extraction was resolved by discussion. In case of missing or unclear information, the corresponding authors of the articles were contacted via email. If the information was still not sufficient for inclusion and evaluation, the study was excluded from the present review.

From the included clinical full-text articles, the following data were extracted: author(s), year of publication, design of study (retrospective study design [RE]/prospective study design [PR]/randomized clinical trial [RCT]), number of included patients and implants, implant material (yttria-stabilized zirconia [YTZP]/alumina-toughened zirconia [ATZ]/titanium), implant design (1-piece/2-piece), implant system, implant surface treatment, surface roughness, market availability of investigated zirconia implant surface (yes/no), type of implant placement (Type 1/2/3/4), use of bone augmentation during surgery (yes/no), use of immediate temporization directly after implant placement (yes/no), immediate loading (yes/no), time period between implant placement and final prosthetic reconstruction (weeks), type of prosthetic restoration on implants and abutments (single crown [SC]/fixed dental partials [FDPs]/removable hybrid dentures [RHDs]), retention modes prosthetics (abutments and prostheses, cement-retained [CR]/screw-retained [SR]), number of drop outs, number of early/late implant failures and implant fractures, mean observation period (months), implant survival (%), and mean peri-implant MBL (mm). Moreover, technical and biological complications as well as PDs were recorded.

### 2.2.4 Quality assessment and risk of bias

Two reviewers (IL and SR) independently screen the included cohort studies and assessed for quality and reporting using the Newcastle–Ottawa scale, which includes 8 key domains. One star is awarded for each domain in which the criteria are fulfilled, except for ‘comparability’ which can be awarded two stars.

### 2.3 Statistical analysis

For survival rates after 60 months, MBL and mean PD, a random-effect meta-analysis was performed using metaprop and metan in Stata statistical software version 17.0 (StataCorp LLC). The amount of heterogeneity across studies was assessed with the I² measure (Higgins et al., 2003). For the survival rates, exact binomial 95% confidence intervals were calculated. Since the survival rates are at 1 in some studies, we enabled the Freeman–Tukey double arcsine transformation to include such studies in the pooled estimate and to guarantee the pooled estimate to be within the [0, 1] interval (Nyaga et al., 2014). For MBL and PD, 95% confidence intervals for means were calculated using standard errors derived from the reported standard deviations.
Forest plots were used for the graphic presentation of survival rates, MBL and mean PD in each study with confidence intervals along with the overall pooled prevalence. In the graphs, the weight of each study to the meta-analyses is represented by the area of a box whose center represents the size of the effect estimated from that study. The confidence interval for the effect from each study is also shown. The summary effect is shown by the middle of a diamond whose left and right extremes represent the corresponding confidence interval.

3 | RESULTS

The electronic database search resulted in 7718 publications (PubMed: 4972; Embase: 1981; Web of Science: 1665, Figure 1). After the removal of duplicates, 5129 titles were available and screened resulting in 580 abstracts for further evaluation. After screening the abstracts, a total of 111 publications were selected for full-text evaluation. After analysis of the included full-text articles, a total of 6 clinical studies fulfilled the inclusion criteria and were included in the present qualitative and quantitative analyses (Figure 1, Tables 1–4). In total, 93 reports had to be excluded (Table 5). The inter-examiner agreement was \( \kappa = 0.82 \).

3.1 | Study characteristics

The literature search has shown that in clinical studies, only zirconia and alumina have been used as alternative implant materials instead of commercially pure titanium, or a specific titanium alloy. Since alumina implants have been removed from the market in the 1990s, only studies investigating zirconia as an implant material were included in the present review.

Based on the eligibility criteria, only observational studies were included for data extraction and further statistical analysis. Altogether, 6 observational clinical cohort studies with prospective (\( n = 4 \)) and retrospective (\( n = 2 \)) designs investigating 1-piece (5 studies, 229 implants) and 2-piece zirconia implant designs (1 study,
### TABLE 1 Characteristics of clinical studies investigating implant survival.

<table>
<thead>
<tr>
<th>Author/year</th>
<th>Study Design</th>
<th>Patients (n)</th>
<th>Impl. Design</th>
<th>Material</th>
<th>Impl. Design</th>
<th>Setting</th>
<th>Company/implant type</th>
<th>Surface treatment</th>
<th>Surface roughness (μm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brunello et al., 2022</td>
<td>RE</td>
<td>48</td>
<td>48</td>
<td>YTZP</td>
<td>2</td>
<td>Univ.</td>
<td>Patent, Zircon-Medical, former ZV3, Zirkon Vision GmbH</td>
<td>Air particle abrading, sintering</td>
<td>Ra 7.0</td>
</tr>
<tr>
<td>Gahlert et al., 2022</td>
<td>PR</td>
<td>44</td>
<td>44</td>
<td>YTZP</td>
<td>1</td>
<td>Priv. pract. and Univ.</td>
<td>Straumann/PURE Ceramic Implant</td>
<td>Sandblasting, large-grit and acid etching</td>
<td>Sa 7.0</td>
</tr>
<tr>
<td>Borgonovo et al., 2021</td>
<td>RE</td>
<td>12</td>
<td>29</td>
<td>YTZP</td>
<td>1</td>
<td>Univ.</td>
<td>Bredent/WhiteSky</td>
<td>Sandblasting</td>
<td>Ra 0.9–1.0</td>
</tr>
<tr>
<td>Balmer et al., 2020</td>
<td>PR</td>
<td>60</td>
<td>71</td>
<td>YTZP</td>
<td>1</td>
<td>Univ.</td>
<td>Vita Zahnfabrik/ceramic. implant Vitadisc</td>
<td>Sandblasting and acid etching</td>
<td>Ra 1.2</td>
</tr>
<tr>
<td>Kohal et al., 2020</td>
<td>PR</td>
<td>40</td>
<td>53</td>
<td>ATZ</td>
<td>1</td>
<td>Univ.</td>
<td>Metoxit AG/Ziraldent FR 1</td>
<td>Sandblasting, Sintering with pore-building polymers</td>
<td>Ra 1.8</td>
</tr>
<tr>
<td>Grassi et al., 2015</td>
<td>PR</td>
<td>17</td>
<td>32</td>
<td>YTZP</td>
<td>1</td>
<td>Priv. pract. and Univ.</td>
<td>Bredent/WhiteSky</td>
<td>Sandblasting</td>
<td>Sa 1.17</td>
</tr>
</tbody>
</table>

Abbreviations: 1, 1-piece implant design; 2, 2-piece implant design; ATZ, alumina-toughened zirconia; Impl. Design, Implant Design; Impl, Implants; PR, prospective study design; Priv. pract.: Private practice; RE, retrospective study design; Ti, Titanium; Univ.: University; YTZP, yttria-stabilized zirconia; NR, not reported.
### TABLE 2  Surgical and prosthetic characteristics of included clinical studies.

<table>
<thead>
<tr>
<th>Author/year</th>
<th>Material</th>
<th>Type implant placement</th>
<th>Simultaneous bone augmentation</th>
<th>Immediate temporization</th>
<th>Immediate loading</th>
<th>Time period placement – Final reconstruction (weeks)</th>
<th>Prosthetics</th>
<th>Retention modes prosthetics (abutments/prostheses)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brunello et al., 2022</td>
<td>YTZP</td>
<td>2,3,4</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Maxilla: 12 Mandible: 10</td>
<td>SC</td>
<td>CR/CR</td>
</tr>
<tr>
<td>Gahlert et al., 2022</td>
<td>YTZP</td>
<td>2,3,4</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>26</td>
<td>SC</td>
<td>~/CR</td>
</tr>
<tr>
<td>Borgonovo et al., 2021</td>
<td>YTZP</td>
<td>2,3,4</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>24</td>
<td>SC/FDP</td>
<td>~/CR; ~/CR</td>
</tr>
<tr>
<td>Balmer et al., 2020</td>
<td>YTZP</td>
<td>2,3,4</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Maxilla: 16 Mandible: 8</td>
<td>SC/FDP</td>
<td>~/CR; ~/CR</td>
</tr>
<tr>
<td>Kohal et al., 2020</td>
<td>ATZ</td>
<td>NR</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Maxilla: 16 Mandible: 8</td>
<td>SC/FDP</td>
<td>~/CR; ~/CR</td>
</tr>
<tr>
<td>Grassi et al., 2015</td>
<td>YTZP</td>
<td>1,4</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>14</td>
<td>SC</td>
<td>~/CR</td>
</tr>
</tbody>
</table>

Abbreviations: ATZ, alumina-toughened zirconia; CR, cement-retained; FDP, fixed dental partials; RHD, removable hybrid denture; SC, single crowns; SR, screw-retained; Ti, titanium; YTZP, yttria-stabilized zirconia.

### TABLE 3  Primary and secondary outcomes of included clinical studies.

<table>
<thead>
<tr>
<th>Author/year</th>
<th>Impl. (n)</th>
<th>Material</th>
<th>Fol. Up after placement (months)</th>
<th>Drop outs implants (n)</th>
<th>Early failures (n)</th>
<th>Late failures (n)</th>
<th>Fractures (n)</th>
<th>Survival rate (%)</th>
<th>Mean MBL (mm ± SD)</th>
<th>Mean probing Depths (mm ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brunello et al., 2022</td>
<td>48</td>
<td>YTZP</td>
<td>111.1</td>
<td>16</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>93.8</td>
<td>0.99 ± 0.58</td>
<td>3.26 ± 1.46</td>
</tr>
<tr>
<td>Gahlert et al., 2022</td>
<td>44</td>
<td>YTZP</td>
<td>60</td>
<td>8</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>97.7</td>
<td>0.99 ± 0.58</td>
<td>NR</td>
</tr>
<tr>
<td>Borgonovo et al., 2021</td>
<td>29</td>
<td>YTZP</td>
<td>120</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>100</td>
<td>0.92 ± 0.97</td>
<td>3.26 ± 1.46</td>
</tr>
<tr>
<td>Balmer et al., 2020</td>
<td>71</td>
<td>YTZP</td>
<td>60</td>
<td>7</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>98.4</td>
<td>0.7 ± 0.6</td>
<td>3.3 ± 0.6</td>
</tr>
<tr>
<td>Kohal et al., 2020</td>
<td>53</td>
<td>ATZ</td>
<td>60</td>
<td>5</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>94.3</td>
<td>0.81 ± 0.77</td>
<td>0.64 ± 0.87</td>
</tr>
<tr>
<td>Grassi et al., 2015</td>
<td>32</td>
<td>YTZP</td>
<td>61.2</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>96.8</td>
<td>1.23 ± 0.29</td>
<td>0.53 ± 0.47</td>
</tr>
</tbody>
</table>

Abbreviations: ATZ, alumina-toughened zirconia; NR, not reported; SD, standard deviation; Ti, titanium; YTZP, yttria-stabilized zirconia.
TABLE 4  Technical and biological complications of implants.

<table>
<thead>
<tr>
<th>Author/year</th>
<th>Impl. (n)</th>
<th>Drop outs implants (n)</th>
<th>Decementation (n)</th>
<th>Abutment fracture (n)</th>
<th>Bone loss &gt;2mm (n)</th>
<th>Soft tissue complications (n)</th>
<th>Peri-implantitis (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brunello et al., 2022</td>
<td>48</td>
<td>16</td>
<td>1</td>
<td>6</td>
<td>NR</td>
<td>13</td>
<td>0</td>
</tr>
<tr>
<td>Gahlert et al., 2022</td>
<td>44</td>
<td>8</td>
<td>NR</td>
<td>NA</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Borgonovo et al., 2021</td>
<td>29</td>
<td>3</td>
<td>NR</td>
<td>NA</td>
<td>0</td>
<td>NR</td>
<td>0</td>
</tr>
<tr>
<td>Balmer et al., 2020</td>
<td>71</td>
<td>7</td>
<td>NR</td>
<td>NA</td>
<td>NR</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Kohal et al., 2020</td>
<td>53</td>
<td>5</td>
<td>NR</td>
<td>NA</td>
<td>4</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Grassi et al., 2015</td>
<td>32</td>
<td>1</td>
<td>NR</td>
<td>NA</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Abbreviations: NA, not applicable due to 1-piece implant design; NR, not reported.

TABLE 5  Excluded studies.

<table>
<thead>
<tr>
<th>Reason for exclusion</th>
<th>Number</th>
<th>Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Too few patients</td>
<td>2</td>
<td>Bittencourt et al. (2021), Steyer et al. (2021)</td>
</tr>
<tr>
<td>Investigated zirconia implants not commercially available</td>
<td>3</td>
<td>Cionca et al. (2021), Koller et al. (2020), Roehling et al. (2016)</td>
</tr>
<tr>
<td>Data not clear for evaluation</td>
<td>1</td>
<td>Oliva et al. (2010)</td>
</tr>
<tr>
<td>Not English</td>
<td>1</td>
<td>Li et al. (2017)</td>
</tr>
</tbody>
</table>

One study did not provide any information regarding MBL (Brunello et al., 2022). 5 studies used periapical radiographs to determine MBL between implant placement and the last follow-up investigation (Balmer et al., 2020; Borgonovo et al., 2021; Gahlert et al., 2022; Grassi et al., 2015; Kohal et al., 2020).

3.4 Probing depths

Altogether, 231 implants placed in 175 patients were evaluated, whereas the PD values ranged between 2.2 mm and 3.3 mm for follow-up periods between 60 and 120 months (Table 3).

The meta-analysis estimated 5-year mean PD values of 3.0 mm (CI 2.6–3.5) and 2.9 mm (CI 2.2–3.7) for retrospective and prospective studies, respectively. Regarding all included studies, the mean 5-year mean PD value was 3.0 mm (CI 2.5–3.4), whereas a substantial degree of heterogeneity was evaluated for the included studies ($I^2 = 69.4\%$, $p = .0$, Figure 4).

One prospective study provided information regarding the presence and incidence of bleeding. However, no information was reported regarding PD (Gahlert et al., 2022).

3.5 Biological complications

All the included studies provided data regarding biological complications. Of the 277 initially placed implants, information was available for 235 implants at the time point of the last clinical and
Table 6: Quality assessment and risk of bias of included observational cohort studies.

<table>
<thead>
<tr>
<th>Author/year</th>
<th>Outcome of interest not present</th>
<th>Comparability of cases and controls</th>
<th>Adequacy of follow-up</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brunello et al., 2022</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>6</td>
</tr>
<tr>
<td>Gahlert et al., 2022</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>6</td>
</tr>
<tr>
<td>Borgono et al., 2021</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>6</td>
</tr>
<tr>
<td>Balmer et al., 2020</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>8</td>
</tr>
<tr>
<td>Kohal et al., 2020</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>8</td>
</tr>
<tr>
<td>Grassi et al., 2015</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>8</td>
</tr>
</tbody>
</table>

Two studies reported on peri-implant infections around zirconia implants (Table 4). Brunello and coworkers investigated a patient population that received 48 2-piece zirconia implants. After a follow-up period of 9 years, information was available for 29 implants. The authors reported that before the 2-year follow-up, 10 implants were diagnosed with peri-implantitis and peri-implant mucositis, respectively. After appropriate treatment, these infections could be successfully treated and no further cases of peri-implantitis could be observed until the last follow-up. However, at the 9-year follow-up, signs of inflammation (bleeding on probing) were observed around 13 implants (Brunello et al., 2022). In another study, peri-implantitis was diagnosed around 1 out of 71 initially placed 1-piece zirconia implants after 5 years of investigation, whereas the implant was included in a cumulative therapy, starting with non-surgical procedures (Balmer et al., 2020). Only 1 study reported MBL of more than 2 mm around 4 out of 53 initially placed implants; however, none of the implants lost more than 3 mm of bone. Interestingly, the authors also evaluated some bone gain after 5 years of investigation around 5 implants (Kohal et al., 2020). Regarding biological complications that were present at the last follow-up, the overall complication rate was 7.7%, whereas the incidences for soft tissue complications, bone loss of more than 2 mm, and peri-implantitis were 5.5%, 1.7% and 0.4%, respectively (Table 4).

3.6 | Technical complications

Only 1 study investigating 48 2-piece zirconia implants provided information regarding technical complications (Table 4). After a mean observation period of 43.7 months, the authors reported the documentation of 1 fiberglass abutment and 1 crown fracture followed by the loosening of the new crown. In addition, 6 fractures of the fiber-glass abutment were registered after a mean observation time of 53.7 months, whereas all fractured abutments could successfully be replaced by new ones (Brunello et al., 2022).

Regarding implant fractures, information was available for 235 implants. Considering all included studies, no zirconia implant fractures were reported (Table 3).

4 | DISCUSSION

In the present systematic review, implant materials other than commercially pure titanium or a specific titanium alloy were evaluated. With regards to zirconia implants, the meta-analysis estimated similar survival rates, MBL and PD values after 5 years compared with published data on titanium implants. Although technical complications regarding implant components were similar, the biological complications showed a minor occurrence of zirconia compared with reported data for titanium as implant material.
At the beginning of 2004, the first zirconia implants were established on the market. Consequently, only studies published after 2000 were selected for data extraction in the present review.

Based on many further developments in implant designs and manufacturing processes within the last 2 decades, it has become difficult to interpret published data on zirconia implants and to evaluate the clinical relevance of the investigated implant type and the reported results. This fact must be considered since even the most recently published clinical studies investigate zirconia implants that have been removed from the market many years ago (Cionca et al., 2021; Koller et al., 2020; Lorenz et al., 2019). From a scientific point of view, the reported data are important and well presented; however, the clinical relevance is rather controversial. A meta-analysis has confirmed that physical properties and ongoing market availability significantly influenced the reported zirconia implant survival rates. In a systematic review, clinical studies investigating zirconia implants that were published between 2004 and 2017 were evaluated. The reported 1-year mean survival rates for commercially available zirconia implants (98.3%) were significantly higher compared with zirconia implants that are not any longer commercially available on the market (91.2%). In addition, a mean 2-year survival rate for commercially available zirconia implants of 97.2% was evaluated. This analysis has clearly shown that zirconia implant survival rates have significantly increased between 2004 and 2017 and that the fracture incidence of zirconia oral implants was significantly reduced from 3.4% to 0.2% (Roehling et al., 2018).

Consequently, the ongoing market clinical availability of the investigated zirconia implants was considered an important inclusion criterion for the present review.

For example, Cionca and coworkers investigated 39 2-piece zirconia implants after a follow-up period of 6 years. However, the evaluated implant type was removed from the market already in 2013 and has been replaced by a further developed generation of implant type in the meantime (Cionca et al., 2021). Thus, this investigation was not considered for data extraction and further analysis.

Since previously published systematic reviews investigating the clinical performance of zirconia implants already estimated mean survival rates and marginal bone level changes up to 2.75 years (Afrashtehfar & Del Fabbro, 2020; Borges et al., 2020; Elnayef et al., 2017; Haro Adánez et al., 2018; Hashim et al., 2016; Pieralli et al., 2017; Roehling et al., 2018), only clinical studies investigating zirconia implants for a minimum of 5 years were included in the present review.
Implant survival was evaluated as the primary outcome. The meta-analysis has estimated a mean survival rate after 5 years of 97.2% (CI 94.7–99.1). This value is similar to previously published systematic reviews investigating titanium implants after 5 years of functional loading. The authors evaluated mean survival rates between 95.6% and 97.2%, early failure rates between 1.3% and 2.4% and late failure rates between 1.5% and 2.7% for SCs and FDPs (Jung et al., 2012; Jung, Pjetursson, et al., 2008; Pjetursson et al., 2012).

MBL and PD as secondary outcomes were also evaluated using meta-analyses. Regarding MBL, the estimated mean MBL after 5 years was 1.1 mm (CI 0.9–1.3). The evaluated data are in accordance with previously published data for zirconia implants after 1 and 2 years of investigation (Borges et al., 2020; Roehling et al., 2018) and similar to data investigating titanium implants after 5 years of follow-up (Aglietta et al., 2009; Karl & Albrektsson, 2017).

Regarding PD, a mean value of 3.0 mm (CI 2.5–3.4) was estimated. Again, the values are similar to previous data investigating titanium implants after follow-up periods of 5 years (range between 2.7 and 3.6 mm [Hosseini et al., 2022; Zembic et al., 2013]).

Considering technical complications, only 1 study provided information regarding 2-piece zirconia implants with cement-retained abutments and SCs and 1 investigation reported on technical complications of SCs cemented on 1-piece zirconia implants (Brunello et al., 2022). In addition, Spies and coworkers investigated the same patient population as Balmer and coworkers and reported data on technical complications regarding the prosthetic suprastructures after a mean follow-up period of 61 (+1.4) months. However, of the 71 placed implants (49 SCs and 22 FDPs), only information was provided regarding 44 SCs placed in molar areas. The authors reported that chipping of the cemented crowns could be observed in 19 patients. Consequently, the authors questioned the concept of bilayered zirconia-based reconstructions and concluded ‘...monolithic approaches might be preferable to overcome this issue...’ (Balmer et al., 2020; Spies et al., 2019). Moreover, the posterior location of the implants and crowns might also have influenced the high-chipping incidence, since in clinical studies, it has been shown that a single crown location had a significant impact on the occurrence of veneer fractures in favor of reconstructions located in the anterior region (Rabel et al., 2018).

The evaluated incidence of soft tissue complications and bone loss of more than 2 mm were 5.5% and 1.7% at the time point of the last follow-up investigation. The values for soft tissue complications are inferior to data on titanium implants reporting values between 7.1% and 8.5% for soft tissue complications and between 5.2% and 2.6% for bone loss of more than 2 mm after 5 years of investigation (Jung et al., 2012; Pjetursson et al., 2012). However, in the latter studies, more implants were evaluated. Regarding peri-implantitis, a low incidence of 0.4% for investigation periods.
FIGURE 4 Forest plot of probing depth values for implants after 5 years. ATZ, alumina-toughened zirconia; CI, confidence intervals; PD, probing depths; YTZP, yttria-stabilized zirconia. Calculations were performed according to the data presented in Table 3.

between 60 and 120 months was evaluated. For titanium implants, incidences of 43% and 22% were evaluated for peri-implant mucositis and peri-implantitis, respectively, whereas a statistically significant positive relationship between the prevalence of peri-implantitis and mean function time were reported (Derks & Tomasi, 2015). In another study, 4591 titanium implants were investigated. The authors reported that the prevalence of peri-implantitis was between 3.6% and 4.7% after 6 to 7 years of follow-up (French et al., 2019). The presently evaluated peri-implantitis incidence for zirconia implants is inferior compared with the data reported in the latter studies. However, it must be considered that in the present review only information for 235 implants was available.

A limitation of the present review is the low number of zirconia implants (n = 277) that were evaluated in the meta-analysis for implant survival. In contrast, systematic reviews investigating titanium implants after 5 years of loading included more than 3223 implants (Jung et al., 2012; Pjetursson et al., 2012). Moreover, only observational studies and no randomized clinical trials were considered in the present review. However, based on the current literature search, 6 RCTs are available, comparing titanium and zirconia implants (Koller et al., 2020; Osman et al., 2014; Payer et al., 2015; Ruiz Henao et al., 2021), immediately and conventionally loaded zirconia implants (Cannizzaro et al., 2010) or porcelain-fused-to-metal and indirect-composite-resin fixed dental prosthetics on zirconia implants (Aldebes et al., 2022). However, 4 studies investigated zirconia implants that are not commercially available, respectively, were removed from the market (Cannizzaro et al., 2010; Koller et al., 2020; Osman et al., 2014; Payer et al., 2015), investigated the same patient population (Koller et al., 2020; Payer et al., 2015) and/or used a novel, unestablished surgical protocol combining alveolar and palatal implants in the maxilla (Osman et al., 2014) or evaluated individually designed, custom-made zirconia implants (Aldebes et al., 2022). Only 1 RCT investigated 16 currently marked available zirconia implants in comparison to 14 titanium implants. After a follow-up period of 12 months, survival rates of 100% for both types of implants and a mean MBL of 2.08 mm (±0.55) and 1.96 mm (±0.48) for zirconia and titanium implants, respectively, were reported (Ruiz Henao et al., 2021).

Based on the low number of included studies, it was not reasonable to perform further statistical methods like meta-regressions to analyze associations between implant survival, MBL as well as PD and study characteristics like type of implant placement, immediate loading, prosthetics, zirconia implant material, and implant design (1-piece compared with 2-piece). In addition, the included studies did not provide detailed data to evaluate the impact of implant location (anterior or posterior) or implant diameter on the reported primary and secondary outcomes. Previously, it has been reported that
implant diameter and implant location influenced technical complications like zirconia implant fractures. The authors of the latter study investigated 170 zirconia implants with an average in situ period of 36.8 ± 5.3 months. They reported 13 implant fractures, whereas all implants were placed in anterior sites and 12 implants had a reduced diameter of 3.25 mm. The authors related the high-fracture rate to notches and scratches created by an uncontrolled manufacture process. However, it must be noted that the investigated fractured zirconia implants have been removed from the market already in 2006 (Gahlert et al., 2012).

5 | CONCLUSIONS

Regarding zirconia implants, the present meta-analyses estimated 5-year mean values of 97.2% (95% CI: 94.7–99.1%), 1.1 mm (95% CI: 0.9–1.3 mm), and 3.0 mm (95% CI: 2.5–3.4 mm) for implant survival, peri-implant MBL and PDs, respectively. Thus, commercially available zirconia implants are a reliable treatment option for follow-up period up to 5 years. Further prospectively designed clinical long-term studies and randomized clinical trials investigating titanium and zirconia implants are needed to confirm the presently evaluated promising outcomes.

AUTHOR CONTRIBUTIONS

S. Roehling: Data curation; Writing – original draft; Writing – review & editing. M. Gahlert: Supervision; Writing – review & editing. M. Bacevic: Conceptualization. H. Woelfler: Statistical Analysis; Visualization. I. Laleman: Data curation; Writing – original draft; Writing – review & editing.

ACKNOWLEDGEMENTS

The authors thank all participants of working group 3 of the 2023 ITI consensus conference. Their suggestions and comments helped in improving this article.

CONFLICT OF INTEREST STATEMENT

The authors report no conflicts of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

REFERENCES


**SUPPORTING INFORMATION**

Additional supporting information can be found online in the Supporting Information section at the end of this article.